

Kinvent Secures Record-Breaking 16 Million Euro Investment for Its Connected Physiotherapy Solution

Kinvent, the European leader in connected physiotherapy solutions, recently announced the securing of a 16 million euro investment during its third round of fundraising. This investment will enable the company to enter a new phase of acceleration, including market penetration in the United States in 2024, increased R&D projects, as well as massive external expansion. To support the company in this phase, French private equity firm Eurazeo is joining the company's leadership.

Dazzling growth for the French nugget

Founded in 2017, Kinvent's groundbreaking solution brought measurable, objective data into physiotherapy. And in doing so, **increasing patient engagement, ensuring better continuity of care, and enabling the implementation of personalized rehabilitation programs.** Since its inception, Kinvent has continued a rapid expansion.

In the midst of growth in a still poorly connected market, Kinvent recorded an **80% growth between 2022 and 2023.** Its **8 sensors, which cover the majority of tests performed in physiotherapy sessions,** have attracted more than **14,000 rehabilitation professionals** (sports specialists, general practitioners, or those working in nursing homes or post-surgical units), healthcare professionals, and even professional sports clubs, spread across **68 countries.**

The company has notably partnered with renowned clubs such as **Montpellier Hérault Rugby, the French Athletics Federation, and the New York Mets,** boosting the company's acclaim internationally.

An ambition: to become the world leader in connected solutions for functional rehabilitation

The private equity firm **Eurazeo**, who was responsible for the investment, is a company dedicated to the development of health sectors in France. The fund takes a **minority stake in the capital**, alongside the founding president and existing minority shareholders including **Unifund, Sofilaro, BADGE, and Raphaël Varane**, among others.

With this latest investment with Eurazeo, Kinvent is now setting out to conquer the global connected physiotherapy device market, starting with the **penetration of the American market.** To achieve its ambitions, **Kinvent can rely on the health expertise and experience of the Nov Santé team** in structuring a rapidly growing company and executing a broad commercial development plan.

"Our teams are delighted to welcome Eurazeo, a leading investment player, so we can build towards the goal of being the world leader in connected solutions for physiotherapy and sports practitioners together. We are at a structuring stage in our history, in a rapidly expanding market, and have been convinced by the Nov Santé team's ability to accompany Kinvent's development, its knowledge of the Health market, and its internal expertise," says **Athanase Kollias, President, and founder of Kinvent.**

"Nearly three years after the fund's launch and a start on development capital, we are opening a new chapter with our first Growth Equity deal. We are very proud that Kinvent has chosen us as the lead investor. The company's expertise, its position as a leader and innovator, as well as the quality of its management team convinced the entire Eurazeo team. This investment aligns perfectly with Nov Santé's strategy to participate in the digitization of a healthcare profession and accelerate the transformation of French and European SMEs," adds **Arnaud Vincent, Managing Director of the Nov Santé Fund at Eurazeo.**

About Kinvent

Founded in 2017 by Athanase Kollias, a former high-level athlete, Kinvent transforms the practice of physiotherapists and fitness trainers through the collection and analysis of biomechanical data. Based in Montpellier, the company designs, develops, and manufactures a range of connected devices that instantly measure force, balance, and range of motion through a single application for the sports performance, rehabilitation, and medical industries.

Key figures:

- 75 employees
- Presence in 68 countries
- 57% of revenue international
- 8 connected sensors linked to a proprietary application
- 14,000 equipped physiotherapists
- 250,000 patients

Learn more about Kinvent : www.kinvent.com

Contact presse :

contact@cd-rp.com – +33 6 34 06 42 72

pour toute demande d'interview ou d'information complémentaire